Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00334750
Recruitment Status : Completed
First Posted : June 8, 2006
Last Update Posted : September 9, 2010
Sponsor:
Information provided by:
Pfizer

Brief Summary:
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.

Condition or disease Intervention/treatment
Glaucoma, Open-Angle Ocular Hypertension Other: There is no intervention in this study.

Layout table for study information
Study Type : Observational
Actual Enrollment : 410 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Study Start Date : November 2007
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Group/Cohort Intervention/treatment
There is no intervention in this study
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Other: There is no intervention in this study.
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.




Primary Outcome Measures :
  1. To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice. [ Time Frame: duration of study ]

Secondary Outcome Measures :
  1. To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation. [ Time Frame: duration of study ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Canadian population
Criteria

Inclusion Criteria:

  • Subjects diagnosed at study visit or within 3 months of visit with OH
  • OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria:

  • No prior treatment for OH or OAG
  • No prior ocular surgery or history of ocular trauma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00334750


Locations
Layout table for location information
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada, T3E 7M8
Pfizer Investigational Site
Edmonton, Alberta, Canada, T5H 0X5
Pfizer Investigational Site
Edmonton, Alberta, Canada, T5H 3V9
Canada, British Columbia
Pfizer Investigational Site
Nanaimo, British Columbia, Canada, V9R 5B6
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V6K 1V7
Pfizer Investigational Site
Williams Lake, British Columbia, Canada, V2G 1H1
Canada, Manitoba
Pfizer Investigational Site
Winnipeg, Manitoba, Canada, R3C 0N2
Canada, Nova Scotia
Pfizer Investigational Site
Sydney, Nova Scotia, Canada, B1P 1P2
Canada, Ontario
Pfizer Investigational Site
Brampton, Ontario, Canada, L6V 1B4
Pfizer Investigational Site
Hamilton, Ontario, Canada, L8M 1L6
Pfizer Investigational Site
London, Ontario, Canada, N6A 4V2
Pfizer Investigational Site
Mississauga, Ontario, Canada, L5L 1W8
Pfizer Investigational Site
Oakville, Ontario, Canada, L6H 3P1
Pfizer Investigational Site
Oakville, Ontario, Canada, L6L 5G8
Pfizer Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Pfizer Investigational Site
Toronto, Ontario, Canada, M5M 1B2
Pfizer Investigational Site
Toronto, Ontario, Canada, M5T 2S8
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H1T 2M4
Pfizer Investigational Site
Montreal, Quebec, Canada, H1V 1G5
Pfizer Investigational Site
Sherbrooke, Quebec, Canada, J1K 1EB
Canada, Saskatchewan
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada, S7K 3H3
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc
ClinicalTrials.gov Identifier: NCT00334750     History of Changes
Other Study ID Numbers: A6111125
First Posted: June 8, 2006    Key Record Dates
Last Update Posted: September 9, 2010
Last Verified: September 2010

Keywords provided by Pfizer:
Glaucoma, Open-Angle Ocular Hypertension Risk factors Canadian

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases